Asthenia, predictor of treatment response in oncology patients in the context of palliative treatmentAstenia, factor predictiv al răspunsului la tratament la pacientul oncologic în contextul tratamentului paliativ

[:en]Niţipir Cornelia (a,b), Panteleimon Iuliana (b) Tebeica Ana-Maria (b) Iaciu Ion-Cristian (b) Barbu Maria Alexandra (b), Radu Irina (b)

(a): MD, PhD, senior oncologist, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
(b): MD, oncologist, SUU Elias, Department of Oncology, Bucharest, Romania

Corresponding author: Niţipir Cornelia: e-mail:

Fatigue associated with neoplastic disease is the most common symptom in these patients whether they follow specific anticancer treatment or supportive treatment. This symptom is subjective and has an important impact on quality of life. The aim of this study was to evaluate the significance and frequency of this fatigue and to analyse the influence of fatigue on quality of life and treatment response.

Material and methods:
We conducted a literature search review of the main articles in Pubmed database.

Were identified many studies with a large number of patients which showed increased levels of fatigue in patients related to impaired performance status, treatment with opioids, lung cancer diagnosis, a history of depression and decreased response to oncological treatment. A Phase II study showed a less favorable pathological response in patients who had moderately severe fatigue during chemotherapy and radiotherapy.

A significant number of studies emphasized the importance of assessing fatigue associated neoplasia. Fatigue is frequently overlooked by physicians. Increased levels of fatigue seem to be correlated with a decreased response to treatment. Also, neoplastic asthenia significantly influences the quality of life.

Key words: asthenia, fatigue, neoplastic disease, quality of life

(Full text in Romanian)

* * * * * * * *
You need to subscribe in order to have access to full texts! If you already subscribed, please login here.

* * * * * * * *
Trebuie să vă abonaţi pentru a avea acces la întregul conţinut! Dacă sunteţi deja abonat, trebuie să vă autentificaţi aici.